UY38137A - A SOLID PHARMACEUTICAL SOLID ORAL DOSAGE FORM - Google Patents
A SOLID PHARMACEUTICAL SOLID ORAL DOSAGE FORMInfo
- Publication number
- UY38137A UY38137A UY0001038137A UY38137A UY38137A UY 38137 A UY38137 A UY 38137A UY 0001038137 A UY0001038137 A UY 0001038137A UY 38137 A UY38137 A UY 38137A UY 38137 A UY38137 A UY 38137A
- Authority
- UY
- Uruguay
- Prior art keywords
- dosage form
- solifenacin
- oral dosage
- solid oral
- solid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a una forma de dosificación oral sólida farmacéutica de solifenacina o una sal farmacéuticamente aceptable de la misma, una resina de intercambio iónico, y uno o más excipientes o vehículos farmacéuticamente aceptables, en la que la solifenacina y la resina de intercambio iónico forman una matriz y la forma de dosificación presenta un perfil de disolución de acuerdo con el que: (i) después de 5 minutos a pH de 6,5 a 7,5, menos de un 10 % p/p del contenido de solifenacina se disuelve, y (ii) después de 30 minutos a pH de 1,0 a 1,6, más de un 80 % p/p del contenido de solifenacina se disuelve. También se refiere a un procedimiento para su preparación, y el uso de la forma de dosificación oral sólida farmacéutica en el tratamiento de síntomas del tracto urinario inferior asociados con el síndrome de vejiga hiperactiva.The present invention relates to a pharmaceutical solid oral dosage form of solifenacin or a pharmaceutically acceptable salt thereof, an ion exchange resin, and one or more pharmaceutically acceptable excipients or carriers, in which solifenacin and the exchange resin Ionic form a matrix and the dosage form has a dissolution profile according to which: (i) after 5 minutes at pH 6.5 to 7.5, less than 10% w / w solifenacin content dissolves, and (ii) after 30 minutes at a pH of 1.0 to 1.6, more than 80% w / w of the solifenacin content dissolves. It also refers to a procedure for its preparation, and the use of pharmaceutical solid oral dosage form in the treatment of lower urinary tract symptoms associated with overactive bladder syndrome.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382149 | 2018-03-08 | ||
| EP18382472 | 2018-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY38137A true UY38137A (en) | 2019-07-31 |
Family
ID=65598664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001038137A UY38137A (en) | 2018-03-08 | 2019-03-06 | A SOLID PHARMACEUTICAL SOLID ORAL DOSAGE FORM |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP2021526504A (en) |
| MX (1) | MX2020009204A (en) |
| TW (1) | TW201938163A (en) |
| UY (1) | UY38137A (en) |
| WO (1) | WO2019170795A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2561167C (en) | 2004-03-25 | 2012-09-11 | Astellas Pharma Inc. | Composition of solifenacin or salt thereof for use in solid formulation |
| JP4277904B2 (en) | 2004-04-30 | 2009-06-10 | アステラス製薬株式会社 | Timed release particulate pharmaceutical composition for oral administration and intraoral quick disintegrating tablet containing the composition |
| EP2146693A2 (en) * | 2007-04-11 | 2010-01-27 | Dr. Reddy's Laboratories Ltd. | Solifenacin compositions |
| LT2572717T (en) * | 2010-05-19 | 2016-09-26 | Astellas Pharma Inc. | Pharmaceutical composition containing solifenacin |
-
2019
- 2019-03-06 UY UY0001038137A patent/UY38137A/en unknown
- 2019-03-07 MX MX2020009204A patent/MX2020009204A/en unknown
- 2019-03-07 WO PCT/EP2019/055666 patent/WO2019170795A1/en active Application Filing
- 2019-03-07 JP JP2020546137A patent/JP2021526504A/en active Pending
- 2019-03-08 TW TW108107840A patent/TW201938163A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019170795A1 (en) | 2019-09-12 |
| MX2020009204A (en) | 2021-01-15 |
| TW201938163A (en) | 2019-10-01 |
| JP2021526504A (en) | 2021-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17013617A (en) | “PHARMACEUTICAL COMBINATION COMPRISING 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL AND NSAID” | |
| EA201591751A1 (en) | TRIPEPTIDE EPOKEKETONE PROTEASE INHIBITORS | |
| CL2019001366A1 (en) | Buffered formulations exendin (9-39). | |
| JP2015517488A5 (en) | ||
| BR112018015718A2 (en) | use of sgc stimulators for the treatment of nonalcoholic steatohepatitis (nash) | |
| SI2889033T1 (en) | Treatment of negative symptoms of schizophrenia with (R)-7-chloro-N-(quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| MX2015009055A (en) | Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant. | |
| PH12019502651A1 (en) | Use of vibegron to treat overactive bladder | |
| JP2016512817A5 (en) | ||
| BR112019003136A2 (en) | multi-unit dosage form of pharmaceutical composition, unit dosage form of pharmaceutical composition, multi-unit / unit dosage form, kit and method of treating a condition treatable by oral administration of a therapeutically active agent | |
| IL292655A (en) | Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies | |
| AR099299A1 (en) | INHIBITOR OF THE CHOLESTERILE ESTER TRANSFER PROTEIN (CETP) AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES | |
| TR201819662T4 (en) | Orally dispersible film composition containing enalapril for the treatment of childhood hypertension. | |
| CL2019002808A1 (en) | Methods to prevent or treat ophthalmic diseases. | |
| UY31826A (en) | PEPTIDE COMPOUND AND ITS USE | |
| EA202090445A1 (en) | ANTIFUNGIC AGENTS WITH INCREASED ACTIVITY AT ACID pH | |
| UY38137A (en) | A SOLID PHARMACEUTICAL SOLID ORAL DOSAGE FORM | |
| UA115250C2 (en) | Pharmaceutical combinations | |
| AR114378A1 (en) | A SOLIFENACIN SOLIFENACIN SOLIFENACIN ORAL SOLID DOSAGE FORM | |
| MX2013001279A (en) | Pharmaceutical composition with a selective enzyme phosphodiesterase inhibitor in an oral gel form. | |
| RU2015122833A (en) | METHOD FOR TREATING CHRONIC ENDOMETRITIS | |
| AR115883A1 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ADDICTION TO PSYCHOACTIVE SUBSTANCES AND / OR FOR THE PREVENTION OF RELIPS TO SUCH ADDICTION | |
| AR068608A1 (en) | NERAMEXAN FOR THE TREATMENT OF NISTAGM | |
| MX2021007324A (en) | Oral therapy using 6,8-bis-benzylthio-octanoic acid. | |
| RU2016147455A (en) | METHOD FOR TREATMENT OF SKIN MANIFESTATIONS OF SCLERODERMA |